RU2005131735A - Химические соединения - Google Patents

Химические соединения Download PDF

Info

Publication number
RU2005131735A
RU2005131735A RU2005131735/04A RU2005131735A RU2005131735A RU 2005131735 A RU2005131735 A RU 2005131735A RU 2005131735/04 A RU2005131735/04 A RU 2005131735/04A RU 2005131735 A RU2005131735 A RU 2005131735A RU 2005131735 A RU2005131735 A RU 2005131735A
Authority
RU
Russia
Prior art keywords
alkyl
nhc
phenyl
heteroaryl
nhs
Prior art date
Application number
RU2005131735/04A
Other languages
English (en)
Inventor
Джон КАММИНГ (GB)
Джон Камминг
Алан ФОЛЛ (GB)
Алан Фолл
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2005131735A publication Critical patent/RU2005131735A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)

Claims (12)

1. Соединение формулы (I)
Figure 00000001
где А отсутствует или представляет собой СН2СН2;
R1 представляет собой галогено, гидрокси, нитро, (СН2)2S(O)k(С1-6алкил), (CH2)nS(O)2NH2, (СН2)nS(O)2NH(С1-6алкил), (CH2)nS(O)2NHCHO, (CH2)nS(O)2N(C1-6алкил)2, OS(O)2(С1-6алкил), циано, С1-6алкил, С1-6алкокси, NH2, NH(С1-6алкил), N(С1-6алкил)2, C(O)NH2, С(O)NH(С1-6алкил), С(O)N(С1-6алкил)2, С(O)[N-связанный гетероциклил], CO2Н, CO2(С1-6алкил), NHC(O)(С1-6алкил), NHC(O)O(С1-6алкил), (СН2)nNHS(O)2(С1-6алкил), С(O)(С1-6алкил), CF3, OCF3, фенил, гетероарил, (С1-4алкил)фенил, (С1-4алкил)гетероарил, NHC(O)фенил, NHC(O)гетероарил, NHC(O)(С1-4алкил)фенил, NHC(O)(С1-4алкил)гетероарил, NHS(O)2фенил, NHS(O)2 гетероарил, NHS(O)2(С1-4алкил)фенил, NHS(O)2(С1-4алкил)гетероарил, NHC(O)NH(С1-6алкил), NHC(O)NH(С3-7циклоалкил), NHC(O)NHфенил, NHC(O)NHгетероарил, NHC(O)NH(С1-4алкил)фенил или NHC(O)NH(С1-4алкил)гетероарил; где вышеуказанные фенильные и гетероарильные группы возможно замещены галогено, гидрокси, нитро, S(O)m(С1-4алкил), S(O)2NH2, S(O)2NH(С1-4алкил), S(O)2N(С1-4алкил)2, циано, С1-4алкилом, С1-4алкокси, C(O)NH2, С(O)NH(С1-4алкил), С(O)N(С1-4алкил)2, CO2Н, CO2(С1-4алкил), NHC(O)(С1-4алкил),NHS(O)2(С1-4алкил), С(O)(С1-4алкил), CF3 или OCF3;
R2 представляет собой фенил, галогенофенил, тиенил или галогенотиенил;
R3 представляют собой водород или метил;
R4 представляет собой пятичленный гетероцикл, содержащий по меньшей мере один атом углерода, от одного до четырех атомов азота и возможно один атом кислорода или серы, где указанный гетероцикл возможно замещен оксо, С1-6алкилом, H2NC(O), (фенилС1-2алкил)NHC(O), С1-2алкил(фенил) (который возможно замещен галогеном, С1-4алкилом, С1-4алкокси, CF3, OCF3, S(С1-4алкил), S(O)(С1-4алкил) или S(O)2(С1-4алкил)), S(С1-4алкил), S(С1-2алкил(фенил)), NH2 или фенилом; причем этот пятичленный гетероцикл возможно конденсирован с циклогексановым, пиперидиновым, бензольным, пиридиновым, пиридазиновым, пиримидиновым или пиразиновым кольцом, где кольцевые атомы углерода указанного конденсированного циклогексанового, пиперидинового, бензольного, пиридинового, пиридазинового, пиримидинового или пиразинового кольца возможно замещены галогеном, циано, С1-4алкилом, С1-4алкокси, CF3, OCF3, NH2, S(С1-4алкил), S(O)(С1-4алкил) или S(O)2(С1-4алкил); и где атом азота конденсированного пиперидинового кольца возможно замещен С1-4алкилом (который возможно замещен оксо, галогеном, ОН, С1-4алкокси, OCF3, C(O)O(С1-4алкил), CN, C(O)NH2, С(O)NH(С1-4алкил), С(O)N(С1-4алкил)2, NH2, NH(С1-4алкил) или N(С1-4алкил)2), С(O)(С1-4алкил) (где алкил возможно замещен С1-4алкокси или фторо), С(O)O(С1-4алкил), C(O)NH2, С(O)NH(С1-4алкил), С(O)N(С1-4алкил)2 или S(O)2(С1-4алкил) (где алкил возможно замещен фторо);
k, m и n независимо равны 0, 1 или 2,
или его фармацевтически приемлемая соль или его сольват.
2. Соединение формулы (I) по п.1, где А отсутствует.
3. Соединение формулы (I) по п.1, где R1 представляет собой галогено, циано, S(O)2(С1-6алкил), OS(O)2(С1-6алкил), CO2(С1-6алкил), NHC(O)(С1-6алкил), NHS(O)2(С1-6алкил), NHC(O)фенил, NHC(O)гетероарил, NHC(O)(С1-4алкил)фенил, NHC(O)(С1-4алкил)гетероарил, NHS(O)2фенил, NHS(O)2 гетероарил, NHS(O)2(С1-4алкил)фенил или NHS(O)2(С1-4алкил) гетероарил, где вышеуказанные фенильные и гетероарильные группы возможно замещены галогено, гидрокси, нитро, S(O)2(С1-4алкил), S(O)2NH2, S(O)2NH(С1-4алкил), S(O)2N(С1-4алкил)2, циано, С1-4алкилом, С1-4алкокси, C(O)NH2, С(O)NH(С1-4алкил), С(O)N(С1-4алкил)2, CO2Н, CO2(С1-4алкил), NHC(O)(С1-4алкил), NHS(O)2(С1-4алкил), С(O)(С1-4алкил), CF3 или OCF3.
4. Соединение формулы (I) по п.1, где R1 представляет собой галогено, циано, S(O)2(С1-6алкил), OS(O)2(С1-6алкил), CO2(С1-6алкил), NHC(O)(С1-6алкил) или NHS(O)2(С1-6алкил).
5. Соединение формулы (I) по п.1, где R2 представляет собой фенил или галогенофенил.
6. Соединение формулы (I) по п.1, где R3 представляет собой водород.
7. Соединение формулы (I) по любому из пп.1-6, где R4 представляет собой имидазолил, 1,2,4-триазолил, 1,2,4-оксадиазолил, тетразолил, пиразолил или 1,3-тиазолил, изоксазолил, возможно замещенные, как описано в п.1.
8. Способ получения соединения формулы (I) по п.1, включающий восстановительное аминирование соединения формулы (II)
Figure 00000002
соединением формулы (III)
Figure 00000003
в присутствии NaBH(ОАс)3 (где Ас представляет собой С(О)СН3) и уксусной кислоты в подходящем растворителе при комнатной температуре.
9. Фармацевтическая композиция, которая содержит соединение по п.1 или его фармацевтически приемлемую соль или его сольват и фармацевтически приемлемый адъювант, разбавитель или носитель.
10. Соединение по п.1 или его фармацевтически приемлемая соль или его сольват для применения в качестве лекарства.
11. Соединение по п.1 или его фармацевтически приемлемая соль или его сольват для применения в изготовлении лекарства для использования в терапии.
12. Способ лечения болезненного состояния, опосредованного CCR5, включающий введение нуждающемуся в таком лечении пациенту эффективного количества соединения по п.1.
RU2005131735/04A 2003-05-09 2004-05-06 Химические соединения RU2005131735A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301369A SE0301369D0 (sv) 2003-05-09 2003-05-09 Chemical compounds
SE0301369-5 2003-05-09

Publications (1)

Publication Number Publication Date
RU2005131735A true RU2005131735A (ru) 2006-06-10

Family

ID=20291267

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005131735/04A RU2005131735A (ru) 2003-05-09 2004-05-06 Химические соединения

Country Status (13)

Country Link
US (1) US7294636B2 (ru)
EP (1) EP1625120A1 (ru)
JP (1) JP2006525999A (ru)
KR (1) KR20060009318A (ru)
CN (1) CN1784393A (ru)
AU (1) AU2004236147A1 (ru)
BR (1) BRPI0410195A (ru)
CA (1) CA2521580A1 (ru)
MX (1) MXPA05011788A (ru)
RU (1) RU2005131735A (ru)
SE (1) SE0301369D0 (ru)
WO (1) WO2004099178A1 (ru)
ZA (1) ZA200508990B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
US7777036B2 (en) * 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
US8121790B2 (en) * 2007-11-27 2012-02-21 Schlumberger Technology Corporation Combining reservoir modeling with downhole sensors and inductive coupling
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
CN102766141B (zh) * 2012-07-31 2014-09-03 温州医学院 8-苄基-3-(3-异丙基-5-甲基-4h-1,2,4-三唑-4-基)-8-氮杂二环[3.2.1]辛烷的制备方法
US20150368648A1 (en) * 2014-06-20 2015-12-24 Yale University Compositions and methods of inhibiting gene expression in a lung
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
US10556899B2 (en) * 2018-02-09 2020-02-11 Sci Pharmtech, Inc. Method for preparing Maraviroc

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) * 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
FR2096916A1 (en) * 1970-07-16 1972-03-03 Synthelabo 1-(3,3-diphenylpropyl)-4-phenyl piperidine - analgesic and antiinflammatory
US4029801A (en) * 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
GB1404868A (en) 1972-12-21 1975-09-03 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
JPS5511670B1 (ru) 1971-07-13 1980-03-26
US3755584A (en) * 1972-04-03 1973-08-28 Abbott Lab Tranquilizers
FR2190430A1 (en) 1972-06-29 1974-02-01 Ferlux N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction
US3818017A (en) * 1973-01-04 1974-06-18 Janssen Pharmaceutica Nv 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US3894030A (en) * 1973-01-04 1975-07-08 Janssen Pharmaceutica Nv 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
GB1425354A (en) 1973-10-10 1976-02-18 Wyeth John & Brother Ltd Indole derivatives
FR2361880A1 (fr) * 1976-04-29 1978-03-17 Science Union & Cie Nouvelles 4-amino piperidines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
GB1538543A (en) * 1976-06-23 1979-01-24 Wyeth John & Brother Ltd N-aminoalkyl piperidine derivatives
GB1532671A (en) 1976-07-16 1978-11-15 Wyeth John & Brother Ltd Piperidine derivatives
GB1586468A (en) * 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
GB1538542A (en) 1977-06-23 1979-01-24 Wyeth John & Brother Ltd Oxime derivatives
US4166119A (en) * 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4264613A (en) * 1979-08-01 1981-04-28 Science Union Et Cie, Societe Francaise De Recherche Medicale Piperidylbenzimidazolinone compounds
FR2469411A1 (fr) * 1979-11-15 1981-05-22 Science Union & Cie Nouveaux derives de la piperidylbenzimidazolinone, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
EP0077427B1 (fr) 1981-10-15 1985-05-22 Synthelabo Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique
EP0095454A3 (de) 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
EP0228893A3 (en) 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
JP2515119B2 (ja) 1987-04-20 1996-07-10 日本ケミフア株式会社 ピペラジン誘導体を含有する活性酸素産生抑制ならびに活性酸素除去作用を有する医薬組成物
DE3715763A1 (de) 1987-05-12 1988-11-24 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
DE3723568C2 (de) 1987-07-16 1994-01-27 Siemens Ag Differenzstromschutzschalter
DK386089A (da) 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
FR2662162B1 (fr) 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
MX9100513A (es) 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
WO1993015052A1 (en) 1992-01-28 1993-08-05 Smithkline Beecham Plc Compounds as calcium channel antagonists
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
ZA935697B (en) 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1994027967A1 (en) 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU7947594A (en) 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
JP2827899B2 (ja) * 1994-04-25 1998-11-25 豊田合成株式会社 チェック弁
WO1996019452A1 (en) 1994-12-21 1996-06-27 Neurosearch A/S A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5892039A (en) 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH0977742A (ja) 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
JP3064425B2 (ja) 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ カルシウムチャンネル・ブロッカーとしてのピペリジン化合物
GB9523526D0 (en) 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINE AND ITS USES.
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
WO1997047299A1 (en) 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
WO1998002151A2 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6015817A (en) 1996-12-05 2000-01-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998031366A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
CA2278309A1 (en) 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
DE19703131A1 (de) 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
BR9814645A (pt) 1997-11-18 2001-07-31 Teijin Ltd Derivados de amina cìclica e seu uso como medicamentos
CA2311921A1 (en) 1997-12-04 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
EP1277737A4 (en) * 2000-03-24 2003-05-07 Meiji Seika Kaisha DIPHENYLALKYLAMINE DERIVATIVES AS AGONISTS OF THE OPIOID -g (d) RECEPTOR
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
GB0104050D0 (en) * 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
US20040110952A1 (en) * 2001-03-01 2004-06-10 Jeremy Burrows N-4-piperidinyl compounds as ccr5 modulators
GB0107228D0 (en) * 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) * 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0103819D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
SE0203828D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
AR042628A1 (es) * 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
SE0203820D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds

Also Published As

Publication number Publication date
MXPA05011788A (es) 2006-01-26
CN1784393A (zh) 2006-06-07
US7294636B2 (en) 2007-11-13
JP2006525999A (ja) 2006-11-16
US20070015788A1 (en) 2007-01-18
ZA200508990B (en) 2007-03-28
EP1625120A1 (en) 2006-02-15
AU2004236147A1 (en) 2004-11-18
SE0301369D0 (sv) 2003-05-09
KR20060009318A (ko) 2006-01-31
CA2521580A1 (en) 2004-11-18
WO2004099178A1 (en) 2004-11-18
BRPI0410195A (pt) 2006-05-23

Similar Documents

Publication Publication Date Title
JP6285440B2 (ja) 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用
AU2004213616B2 (en) A process of preparing imatinib
JP2008513498A5 (ru)
HUE034347T2 (en) N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
RU2006134020A (ru) Конденсированные производные пиразола
RU2712196C2 (ru) Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии
KR101718596B1 (ko) 티에닐[3,2-d]피리미딘-4-온 화합물, 그 제조방법, 약물조성물 및 용도
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
CA2529686C (en) 2-acylaminothiazole derivative or salt thereof
RU2003114748A (ru) Новые соединения, не являющиеся имидазолами
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
RU2006130684A (ru) Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
RU2007106928A (ru) Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
JP2006524222A5 (ru)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2021514981A (ja) ２，４−ジアミノキナゾリン誘導体、及びその医学的用途
JP2008503575A5 (ru)
RU2005131735A (ru) Химические соединения
US6420424B1 (en) CCR-3 receptor antagonists
KR20070007759A (ko) 바이러스 복제 억제제로서 유용한 치환된 아릴티오우레아유도체
RU2006146877A (ru) Химическое соединение 1
JP2016079168A (ja) ９員縮合環誘導体
RU2004111601A (ru) Пиперидиновые производные и их применение в качестве модуляторов активности р ецепторов хемокина (в частности ccr5)
RU2004112781A (ru) Производные пиперидина и их применение в качестве модуляторов активности рецепторов хемокинов (в частности ccr5)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20070615